Production and Characterization of Fusion Proteins Containing Transferrin and Nerve Growth Factor

References

• Albeck D. S., Hoffer B. J., Quissell D., Sanders L. A., Friden P. M., Zerbe G., Granholm A. A non-invasive transport system for Gdnf across the blood-brain barrier. Neuro Report
   PubMed Web of Science ®Google Scholar
• Aruffo A., Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Nat. Acad. Sci. USA 1987; 84: 8573–8577
   PubMed Web of Science ®Google Scholar
• Backman C., Rose G. M., Hoffer B. J., Henry M., Bartus R. T., Friden P., Granholm A. C. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J. of Neuroscience 1996; 16: 5437–5442
   PubMed Web of Science ®Google Scholar
• Bailey S., Evans R. W., Garratt R. C., Gorinsky B., Hasnain S., Horsburgh C., Jhoti H., Lindley P. F., Mydin A., Sarra R., Watson J. Molecular structure of serum transferrin at 3.3-A resolution. Biochemistry 1988; 27: 5804–5812
   PubMed Web of Science ®Google Scholar
• Banks W. A., Kastin A. J., Fasold M. B., Barrera CM., Augereau G. Studies of the slow bidirectional transport of iron and transferrin across the blood-brain barrier. Brain Res. Bull 1988; 21: 881–885
   PubMed Web of Science ®Google Scholar
• Barde Y. A. Trophic factors and neuronal survival. Neuron 1989; 2: 1525–1534
   PubMed Web of Science ®Google Scholar
• Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmac. Ther 1994; 64: 127–154
   PubMed Web of Science ®Google Scholar
• Bebbington C. R. Expression of antibody genes in nonlymphoid mammalian cells. Methods: A Companion to Methods in Enzymology 1991; 2: 136–145
   Google Scholar
• Bickel U., Yoshikawa T., Landaw E. M., Faull K. F., Pardridge W. M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 1993; 90: 2618–2622
   PubMed Web of Science ®Google Scholar
• Blomer U., Naldini L., Verma I. M., Trono D., Gage F. Applications of gene therapy to the CNS. Human Molecular Genetics 1996; 5: 1397–1404
   PubMed Web of Science ®Google Scholar
• Bradshaw R. A., Murray-Rust J., Ibanez C. F., McDonald N. Q., Lapatto R., Blundell T. L. Nerve growth factor: structure/function relationships. Protein Science 1994; 3: 1901–1913
   PubMed Web of Science ®Google Scholar
• Brinkman U., Buchner J., Pastan I. Independent domain folding of Pseudomonas exotixin and single-chain immunotoxins: Influence of interdomain connections. Proc. Acad. Natl. Sci. USA 1992; 89: 3075–3079
   PubMed Web of Science ®Google Scholar
• Broadwell R. A., Banks W. A. A cell biological perspective for the transcytosis of peptides and proteins through the mammalian blood-brain fluid barriers. The Blood-Brain Barrier: Cellular and Molecular Biology, W. A. Pardridge. Raven Press, New York 1993; 165–199
   Google Scholar
• Broadwell R. D., Balin B. J., Salcman M. Transcy-totic pathway for blood-borne protein through the blood-brain barrier. Proc. Natl. Acad. Sci. USA 1988; 85: 632–636
   PubMed Web of Science ®Google Scholar
• Brock J. H. Transferrins. Metallo Proteins: Part 2: Metal Proteins with Non-redox Roles, P. Harrison. Verlag Chemie, Weinheim 1985; 183–261
   Google Scholar
• Camarata P. J., Suryanarayanen R., Turner D. A., Parker R. G., Ebner T. J. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 1992; 30: 313–319
   PubMed Web of Science ®Google Scholar
• Dangl J. L., Wensel T. G., Morrison S. L., Stryer L., Herzenberg L. A., Oi V. T. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988; 7: 1989–1994
   PubMed Web of Science ®Google Scholar
• Ebendal T. NGF in CNS: Experimental data and clinical implications. Progress in Growth Factor Research 1989; 1: 143–159
   PubMedGoogle Scholar
• Fishman J. B., Rubin J. B., Handrahan J. V., Connor J. R., Fine R. E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res 1987; 18: 299–304
   PubMed Web of Science ®Google Scholar
• Frank S., Krasznai K., Durovic S., Lobentanz E., Dieplinger H., Wagner E., Zatloukal K., Cotten M., Utermann G., Kostner G., Zechner R. High level expression of various apolipoprotein(a) isoforms by “transferrinfection”: The role of kringle IV sequences in the extracellular association with low-density lipoprotein. Biochemistry 1994; 33: 12329–12339
   PubMed Web of Science ®Google Scholar
• Friden P. M. Receptor-mediated transport of peptides and proteins across the blood-brain barrier. The Blood-Brain Barrier, W. M. Pardridge. Raven Press, Ltd., New York 1993; 229–247
   Google Scholar
• Friden P. M., Walus L. R., Musso G. F., Taylor M. A., Malfroy B., Starzyk R. M. Anti-transferrin receptor antibody and antibody-drug conjugate cross the blood-brain barrier. Proc. Nat. Acad. Sci. USA 1991; 88: 4771–4775
   PubMed Web of Science ®Google Scholar
• Friden P. M., Walus L. R., Watson P., Doctrow S. R., Kozarich J. W., Backman C., Bergman H., Hoffer B., Bloom F., Granholm A. C. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993; 259: 373–377
   PubMed Web of Science ®Google Scholar
• Granholm A. C., Backman C., Bloom F., Ebendal T., Gerhardt G. A., Hoffer B., Mackerlova L., Olson L., Soderstrom S., Walus L. R., Friden P. M. NGF and anti-transferrin receptor antibody conjugate: short and long-term effects on survival of cholinergic neurons in intraocular septal transplants. J. Pharmacol, and Exp. Ther 1994; 268: 448–459
   PubMed Web of Science ®Google Scholar
• Hefti F., Hartikka J., Knusel B. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiology of Aging 1989; 10: 515–533
   PubMed Web of Science ®Google Scholar
• Hempstead B. L., Rabin S. J., Kaplan L., Reid S., Parada L., Kaplan D. R. Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. Neuron 1992; 9: 883–896
   PubMed Web of Science ®Google Scholar
• Hopkins C. R. Cell 1985; 40: 199–208
   PubMed Web of Science ®Google Scholar
• Jaenicke R. Folding and association of proteins. Prog. Biophys. Mol. Biol 1987; 49: 117–237
   PubMed Web of Science ®Google Scholar
• Jeffries W. A., Brandon M. R., Hunt S. V., Williams A. F., Gatter K. C., Mason D. Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162–163
   PubMed Web of Science ®Google Scholar
• Kordower J. H., Charles V., Bayer R., Bartus R. T., Putney S. D., Walus L. R., Friden P. M. Intravenous administration of an antibody-nerve growth factor conjugate prevents degeneration of cholinergic striatal neurons in a model of Huntington's disease. Proc. Natl. Acad. Sci. USA 1994a; 91: 9077–9080
   PubMed Web of Science ®Google Scholar
• Kordower J. H., Winn S. R., Liu Y., Mufson E. J., Sladek J. R., Hammang J. P., Baetge E. E., Emerich D. F. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. USA 1994b; 91: 10898–10902
   PubMed Web of Science ®Google Scholar
• Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44: 283–292
   PubMed Web of Science ®Google Scholar
• Krewson C. E., Saltzman W. M. Transport and elimination of recombinant human NGF during long-term delivery to the brain. Brain Research 1996; 727: 169–181
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237: 1154–1162
   PubMed Web of Science ®Google Scholar
• Lindner M. D., Kearns C. E., Winn S. R., Frydel B., Emerich D. F. Effects of intraventricular encapsulated hNGF-secreting fibroblasts in aged rats. Cell Transpi 1996; 5: 205–223
   PubMed Web of Science ®Google Scholar
• Maniatis T., Fritsch E. F., Sambrook J. Molecular cloning: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor 1989
   Google Scholar
• Marsh J. W., Meville J. D. M. A flexible peptide spacer increases the efficacy of holoricin and anti-T cell immunotixins. J. Immunol 1988; 140: 3674–3678
   PubMed Web of Science ®Google Scholar
• Maysinger D., Jalsenjak I., Cuello A. C. Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions 1992; 140: 71–74
   Google Scholar
• McDonald N. Q., Chao M. V. Structural determinants of Neurotrophin action. J. Biol. Chem 1995; 270: 19669–19672
   PubMed Web of Science ®Google Scholar
• McDonald N. Q., Lapatto R., Murray-Rust J., Gunning J., Wlodawer A., Blundell T. L. New protein fold revealed by a 2.3 A resolution crystal structure of nerve growth factor. Nature 1991; 354: 411–414
   PubMed Web of Science ®Google Scholar
• McGrath J. P., Cao X., Schutz A., Lynch P., Ebendal T., Coloma M. J., Morrison S. L., Putney S. D. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J. Neurosci. Res 1997; 47: 123–133
   PubMed Web of Science ®Google Scholar
• Mobley W. C. Nerve growth factor in Alzheimer's disease: to treat or not to treat?. Neurobiology of Aging 1989; 10: 578–580
   PubMed Web of Science ®Google Scholar
• Pardridge W. M. Peptide Drug Delivery to the Brain. Raven Press, New York 1991
   Google Scholar
• Pardridge W. M., Boado R. J., Kang Y. S. Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA 1995a; 92: 5592–5596
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Kang Y. S., Buciak J. L. Transport of human recombinant brain-derived neutotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector mediated peptide drug delivery. Pharmaceutical Research 1994; 11(5)738–746
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Kang Y. S., Buciak J. L., Yange J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmaceutical Research 1995b; 12(6)807–816
   PubMed Web of Science ®Google Scholar
• Pastan I., Fitzgerald D. Recombinant toxins for cancer treatment. Science 1991; 254: 1173–1177
   PubMed Web of Science ®Google Scholar
• Ridet J. L., Privat A. Gene therapy in the central nervous system: direct versus indirect gene delivery. J. Neurosci. Res 1995; 42: 287–293
   PubMed Web of Science ®Google Scholar
• Saffran B. N., Woo J. E., Mobley W. C., Crutcher K. A. Intraventricular NGF infusion in the mature rat brain enhances sympathetic innervation of cerebrovascular targets but fails to elicit sympathetic ingrowth. Brain Res 1989; 492: 245–254
   PubMed Web of Science ®Google Scholar
• Saito Y., Buciak J., Yang J., Pardridge W. M. Vector-mediated delivery of 125-labeled beta-amyloid A beta 1–40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1–40/vector complex. Proc. Natl. Acad. Sci. USA 1995; 92: 10227–10231
   PubMed Web of Science ®Google Scholar
• Shin S., Friden P., Moran M., Morrison S. L. Functional properties of antibody insulin-like growth factor fusion proteins. J. Biol. Chem 1994; 269: 4979–4985
   PubMed Web of Science ®Google Scholar
• Shin S., Morrison S. L. Expression and characterization of an antibody binding specificity joined to insulin-like growth factor-I: Potential applications for cellular targeting. Proc. Natl. Acad. Sci. USA 1990; 87: 5322–5326
   PubMed Web of Science ®Google Scholar
• Shin S. U., Friden P., Moran M., Olson T., Kang Y. S., Pardridge W., Morrison S. L. Transferrin-anti-body fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. USA 1995; 92: 2820–2824
   PubMed Web of Science ®Google Scholar
• Skarlatos S., Yoshikawa T., Pardridge W. M. Transport of [125I] transferrin through the rat blood-brain barrier. Brain Research 1995; 683: 164–171
   PubMed Web of Science ®Google Scholar
• Smith A. P., Varon S., Shooter E. M. Multiple forms of the nerve growth factor protein and its subunits. Biochemistry 1968; 7: 3259–3268
   PubMed Web of Science ®Google Scholar
• Suter U., Heymach J. V., Shooter E. M. Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 1991; 10: 2395–2400
   PubMed Web of Science ®Google Scholar
• Taylor E. M., Crowe A., Morgan E. H. Transferrin and iron uptake by the brain: effects of altered iron status. J. Neurochem 1991; 57: 1584–1592
   PubMed Web of Science ®Google Scholar
• Thoenen H., Bandtlow C., Heumann R. The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev. Physiol. Biochem. Pharmacol 1987; 109: 145–178
   PubMed Web of Science ®Google Scholar
• Trowbridge I., Collawn J., Hopkins C. R. Signal-dependent membrane protein trafficking in the endocytic pathway. Ann. Rev. Cell Biol 1993; 9: 129–161
   PubMedGoogle Scholar
• Turkewitz A. P., Amatruda J. F., Borhani D., Harrison S. C., Schwartz A. L. A high yield purification of the human transferrin receptor and properties of its major extracellular fragment. J. Biol. Chem 1988; 263: 8318–8325
   PubMed Web of Science ®Google Scholar
• Ulrich A., Gray A., Berman C., Dull T. J. Human nerve growth factor gene sequence highly homologous to that of mouse. Nature 1983; 303: 821–825
   PubMed Web of Science ®Google Scholar
• Vinod C., Mufson E. J., Friden P. M., Bartus R. T., Kordower J. H. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Research 1996; 728: 193–203
   PubMed Web of Science ®Google Scholar
• Wagner E., Zatloukal K., Cotten M., Kirlappos H., Mechtler K., Curiel D., Birnstiel M. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci 1992; 89: 6099–6103
   PubMed Web of Science ®Google Scholar
• Walus L. R., Pardridge W. M., Starzyk R. M., Friden P. M. Enhanced uptake of CD4 across the rodent and primate blood-brain barrier following conjugation to anti-transferrin receptor antibodies. J. Pharmacol, and Exp. Ther 1996; 277: 1067–1075
   PubMed Web of Science ®Google Scholar
• Watts C. J. Cell Biol 1985; 100: 633–637
   PubMed Web of Science ®Google Scholar
• White S. R. T., Seligman P. A., Rutherford M., Trowbridge I. S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res 1990; 50: 6295–6301
   PubMed Web of Science ®Google Scholar
• Yang F., Lum J. B., McGill J. R., Naylor S. L., van Bragt B. H., Baldwin W. D., Bowman B. H. Human transferrin: cDNA characterization and chromosomal localization. Proc. Nat. Acad. Sci. USA 1984; 81: 2752–2756
   PubMed Web of Science ®Google Scholar